Biotech/Medical Tech Stock News from Investorideas.com

Friday, February 25, 2022

New #Stocks to Watch at Investor Ideas: (NASDAQ: $AMLX) (NASDAQ: $CINC) (NASDAQ: $HILS) (NASDAQ: $VIGL) (CSE: $HYTN.C) (CSE: $CMT.C)

New #Stocks to Watch at Investor Ideas: (NASDAQ: $AMLX) (NASDAQ: $CINC) (NASDAQ: $HILS) (NASDAQ: $VIGL) (CSE: $HYTN.C) (CSE: $CMT.C)

New #Biotech, #Cannabis and #Mining Stocks to Watch

Vancouver, Kelowna, Delta, BC, February 25, 2022 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Cannabis and Mining. Today’s stocks have been added to our lists of free stock directories in each sector.

Read this in full at https://www.investorideas.com/news/2022/main/02251Stocks.asp

The newest biotech companies are involved in the treatment of ALS, hypertension, cancer and neurodegenerative diseases, respectively.

The latest cannabis and mining companies are both newly-listed on the CSE (Canadian Stock Exchange).

New stocks added to the Biotech Stocks Directory:

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a clinical-stage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

CinCor Pharma, Inc. (NASDAQ:CINC) founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.

Hillstream BioPharma Inc. (NASDAQ:HILS) is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers. Hillstream’s most advanced candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to be efficacious in a clinical pilot study in Germany in devastating cancers, including triple negative breast cancer and epithelial carcinomas. Hillstream intends to start a clinical study with HSB-1216 in 2022 to expand upon the existing early clinical proof-of-concept. Hillstream uses Quatramer™, its proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity. In addition, Trident Artificial Intelligence, Hillstream’s artificial intelligence precision medicine platform, is used to identify biomarkers in our clinical programs to target a specific patient segment most likely to benefit.

Vigil Neuroscience, Inc. (NASDAQ:VIGL) is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families.

New stocks added to the Cannabis Stocks Directory:

HYTN Innovations Inc (CSE:HYTN) formulates, manufactures, markets, and sells premium cannabis goods. With the mission to be the leading provider of consistent, natural, and delicious cannabis products, HYTN focuses its efforts on identifying category opportunities and takes an innovative approach to delivering elevated cannabis experiences to a discerning customer base.

New stocks added to the Mining Stocks Directory:

Cullinan Metals Corp. (CSE:CMT) is a mineral exploration company with a focus on exploration and discovery. We create value for our shareholders by engaging in promising mineral exploration opportunities. Our goal is to advance projects from discovery all the way to production. This vertically integrated strategy allows Cullinan Metals to achieve shareholder value through the entire life-cycle of the mining process.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast.

Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

Contact Investorideas.com

800 665 0411

Friday, February 11, 2022

New #Stocks to Watch at Investor Ideas: (Nasdaq: $TIVC) (Nasdaq: $BJDX) (Nasdaq: $MYNZ) (CSE: $CRIV.C)

New #Stocks to Watch at Investor Ideas: (Nasdaq: $TIVC) (Nasdaq: $BJDX) (Nasdaq: $MYNZ) (CSE: $CRIV.C)

Biotech and Mining Stocks to Watch

Vancouver, Kelowna, Delta, BC, February 11, 2022 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech and Mining. Today’s stocks have been added to our lists of free stock directories in each sector.

Read this in full at https://www.investorideas.com/news/2022/main/02111Stocks.asp

New biotech companies are all involved in life sciences, while the latest mining company is involved in precious and base metals exploration.

New stocks added to the Biotech Stocks Directory:

Tivic Health Systems, Inc. (Nasdaq:TIVC) is a commercial-phase healthtech company delivering non-invasive bioelectronic treatments that provide consumers choice in the treatment of inflammation and related conditions.

Bluejay Diagnostics, Inc. (Nasdaq: BJDX) is a late-stage, pre-revenue diagnostics company focused on improving patient outcomes through the Symphony System, a more cost-effective, rapid, near-patient product candidate for triage and monitoring of disease progression in hospital and long-term acute care (LTAC) settings. Bluejay’s first product candidate, an IL-6 test for sepsis triage, is designed to provide accurate, reliable results in approximately 24 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions

Mainz Biomed B.V. (Nasdaq: MYNZ) develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

New stocks added to the Mining Stocks Directory:

Carson River Ventures Corp. (CSE:CRIV) is engaged in the business of mineral exploration to locate and develop economic precious and base metals properties of merit. The Company has a well seasoned Management Team, with extensive Public Company experience and relationships within the industry. The Company’s principle project is the Chucker property, located in Mineral County, Nevada, within the Prolific Walker Lane gold trend.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

About Investorideas.com - News that Inspires Big Investing Ideas

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Friday, January 28, 2022

New #Stocks to Watch at Investor Ideas: (Nasdaq: $GNTA) (Nasdaq: $IMMX) (Nasdaq: $NRSN) (Nasdaq: $CING) (CSE: $JKPT.C)

New #Stocks to Watch at Investor Ideas: (Nasdaq: $GNTA) (Nasdaq: $IMMX) (Nasdaq: $NRSN) (Nasdaq: $CING) (CSE: $JKPT.C)

Biotech and Gaming Stocks to Watch

Vancouver, Kelowna, Delta, BC, January 28, 2022 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech and Gaming. Today’s stocks have been added to our lists of free stock directories in each sector.

Read this in full at https://www.investorideas.com/news/2022/main/01281Stocks.asp

The newest biotech companies are involved in cancer treatments & oncology, neurodegenerative diseases such as Parkinson’s ALS & Alzheimer’s and the treatment of ADHD.

The latest gaming company is an international online service provider for lottery, casino, and sportsbook gambling.

New stocks added to the Biotech Stocks Directory:

Genenta Science S.p.A. (NASDAQ:GNTA) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.

Immix Biopharma, Inc. (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma, a life-threatening form of cancer in children. RPPD qualifies ImmixBio to receive fast track review and a priority review voucher (PRV) at the time of marketing approval of IMX-110. Our proprietary SMARxT Tissue-Specific™ Platform produces drug candidates that circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all 3 components of the tumor micro-environment (TME). We believe ImmixBio’s TME Normalization™ technology severs the lifelines between the tumor and its metabolic and structural support

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. Due to the complexity of neurodegenerative diseases, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

Cingulate Inc. (NASDAQ:CING) is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates. CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) are engineered using an innovative, versatile platform technology that will enable the formulation and manufacturing of single-dose, multi-release tablets designed to deliver a rapid onset and last the entire active-day, while providing a controlled descent of drug to optimize treatment. Cingulate’s formulation will be designed as a once-daily, multi-release tablet with clear differentiation and compelling advantages over current treatment options. Cingulate is headquartered in Kansas City.

New stocks added to the Gaming Stocks Directory:

Kings Entertainment Group Inc. (CSE:JKPT) is the parent company of global lottery brands LottoKings and WinTrillions. As international online service providers for lottery, casino, and sportsbook gambling, these brands leverage their ability to acquire pre-qualified players through renowned lottery offerings, then engage players in a range of casino and sportsbook offerings. LottoKings and WinTrillions have attracted and retained millions of player sign-ups since. their inceptions.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

About Investorideas.com - News that Inspires Big Investing Ideas

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Thursday, January 27, 2022

Breaking #AI #Health #Stock News: GBT (OTCPK: $GTCH) is Evaluating an Implementation of Advanced NLP Algorithm, To Provide Powerful NLP Features for Its AI #Healthcare Advisory System; #artificialintelligence

Breaking #AI #Health #Stock News: GBT (OTCPK: $GTCH) is Evaluating an Implementation of Advanced NLP Algorithm, To Provide Powerful NLP Features for Its AI #Healthcare Advisory System; #artificialintelligence

The Advanced NLP (Natural Language Processing) capabilities to enhance the human-to-computer interaction experience, capable of making it significantly more user friendly, mainly intuitive

San Diego, CA, January 27, 2022 - (Investorideas.com Newswire) GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”), is evaluating the use of advanced NLP algorithm model to enhance its AI based healthcare advisory system human interaction experience. The Text-To-Text Transfer Transformer (T5) model introduces an efficient technology to perform a wide variety of supervised Natural Language Processing (NLP) tasks such as classification, Q&A and summarization. Typically, most of the new deep learning NLP models are very large and include vast number of parameters. Normally the larger the NLP model, the more learning capacity it has, yet one of the main disadvantages is the huge dataset which may reduce the overall performance. The advanced NLP algorithm model is considered one of the most advanced, high performance NLP algorithms that includes a vast number of parameters, using significantly less memory, and provides high accuracy. GBT will be evaluating the T5, pre-trained model with the goal of using it in its Hippocrates healthcare advisory system, handling Q/A, text, summarization and compositional commonsense knowledge. The model allows more parallel processing than methods like Recurrent Neural Network (RNN) and Convolutional Neural Network CNN) which significantly increases data understanding and reasoning capabilities. For example, T5 model is capable of processing words together rather than on a word-by-word of a given text. As global data realm is estimated to reach zettabytes range in the near future, our deep learning computing will need powerful processing capabilities, comprehending and scrutinizing data, particularly in the huge, unstructured NLP domain. The system is designed to perform as a general health Q/A advisory system, providing first-line of health-related advice. We plan to further develop the system to include intelligent telemedicine capabilities that will assist patients and healthcare specialists through global connected devices.

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2022/01271NLP-Algorithm.asp

“Natural Language processing (NLP) is currently broadly used for the various tasks involving sentiment analysis, for example spam email detection, textual/voice driven virtual assistants, chatbots, and similar. In the last decade, deep learning technology have become more powerful, allowing larger data and faster processing models to handle the constantly growing unstructured data. The amount of unstructured data has become a challenge for information analysis especially within the NLP arena due to compositional complexity and the demand for a human-alike interaction. Today’s voice and text digital assistants are expected to efficiently “understand” verbal or textual conversations, exactly as an in-person interaction. Artificial General Intelligence (AGI) is our machine learning solution to “understand” the data, reason and make decisions exactly as a human would do. One of the key challenges for such system is to comprehend humans natural language, interpret, and manipulate it, which is exactly what NLP is. Our Avant! deep neural networks already encapsulate vast computing power, allowing larger language models with faster processing. We are seeking new capabilities by combining new NLP models with our current technology to better “understand” users, their intent, and providing accurate, well summarized, response. We are evaluating if the possible implementation of the T5 model within our Hippocrates healthcare AI system may produce much more robust level of user’s chat interaction with more human-alike dialog, mainly intuitive. The Hippocrates healthcare advisory system is aimed to provide first line health related advice and to become an assisting tool for the general population and healthcare professionals. Its human interaction aspect, via a robust NLP technology, is one of the most important features to ensure viable and accurate health related advice information,” provided Danny Rittman, the Company’s CTO.

There is no guarantee that the Company will be successful in researching, developing or implementing this system. In order to successfully implement this concept, the Company will need to raise adequate capital to support its research and, if successfully researched, developed and granted regulatory approval, the Company would need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product. There is no guarantee that the Company will be successful in any or all of these critical steps.

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

Get News Alerts on GBT Technologies Inc GTCH

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Get more tech stocks investor ideas- news, articles, podcasts and stock directories

Disclaimer

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investorideas.com newswire, breaking biotechnology and pharma news

Friday, February 25, 2022

New #Stocks to Watch at Investor Ideas: (NASDAQ: $AMLX) (NASDAQ: $CINC) (NASDAQ: $HILS) (NASDAQ: $VIGL) (CSE: $HYTN.C) (CSE: $CMT.C)

Friday, February 11, 2022

New #Stocks to Watch at Investor Ideas: (Nasdaq: $TIVC) (Nasdaq: $BJDX) (Nasdaq: $MYNZ) (CSE: $CRIV.C)

Friday, January 28, 2022

New #Stocks to Watch at Investor Ideas: (Nasdaq: $GNTA) (Nasdaq: $IMMX) (Nasdaq: $NRSN) (Nasdaq: $CING) (CSE: $JKPT.C)

Thursday, January 27, 2022

Breaking #AI #Health #Stock News: GBT (OTCPK: $GTCH) is Evaluating an Implementation of Advanced NLP Algorithm, To Provide Powerful NLP Features for Its AI #Healthcare Advisory System; #artificialintelligence